Read the Annual Meeting Abstracts
ASGCT Staff - April 27, 2021
Read our collection of the latest gene and cell therapy research ahead of presentation at the 24th Annual Meeting.
We are proud to share our collection of abstracts that will be presented at the 24th Annual Meeting! Read about the most innovative science in the field from more than 800 pieces of research that are now available digitally and as a PDF.
Below you'll find highlights from the research, including the Top Abstracts, which will be presented during the Presidential Symposium on May 13, and the Clinical Trials Spotlight abstracts, which will be presented during the Clinical Trials Spotlight Symposium on May 14.
Read the Digital Abstracts Download the PDF
Presentation of the Top Abstracts
Thursday, May 13, 3:30-5:15 p.m. (ET)
127. Base Editing Rescues Sickle Cell Disease in Human Hematopoietic Stem Cells and in Mice
Jonathan Yen, Ph.D., St. Jude Children’s Research Hospital
128. Safety and Efficacy Results with a Single Dose of Autologous CRISPR-Cas9-Modified CD34+ Hematopoietic Stem and Progenitor Cells (HSPCs) in Transfusion-Dependent β-Thalassemia (TDT) and Sickle Cell Disease (SCD)
Tony W. Ho, M.D., CRISPR Therapeutics
129. Immunostimulatory Bacterial Antigen-Armed Oncolytic Measles Virotherapy Significantly Increases the Potency of Anti-PD1 Checkpoint Therapy
Eleni Panagioti, Ph.D., Mayo Clinic
130. In-Vivo Engineered B Cells Retain Memory and Secrete High Titers of Anti-HIV Antibodies in Mice
Alessio David Nahmad, M.Sc., Tel Aviv University
Clinical Trials Spotlight Symposium
Friday, May 14, 10-11:45 a.m. (ET)
194. Systemic AAV Delivery Activates the Classical Complement Pathway Leading to Thrombotic Microangiopathy
Stephanie Salabarria, BH.Sc., University of Florida
195. Activity of Banked (Off-the-Shelf) CD30. CAR-Modified Epstein-Barr Virus-Specific T Cells in Patients with CD30-Positive Lymphoma
David Quach, Ph.D.
196. Updated Results From HGB-206 LentiGlobin for Sickle Cell Disease Gene Therapy Study: Group C Data and Group A AML Case Investigation
John Tisdale, M.D., National Institutes of Health
197. ADVM-022 Intravitreal Gene Therapy for Neovascular AM.D. - Results From the Phase 1 OPTIC Study
Szilárd Kiss, M.D., Weill Cornell Medicine
198. Natural Killer T Cells Expressing a GD2-CAR and IL-15 Are Safe and Can Induce Complete Remission in Children with Relapsed Neuroblastoma - A First-in-Human, Phase 1 Trial
Andras Heczey, M.D., Baylor College of Medicine
199. Long Term Follow Up for the Development of Subsequent Malignancies in Patients Treated With Genetically Modified Immune Effectors
David Steffin, M.D., Baylor College of Medicine
200. Updated Results of Transpher A, a Multicenter, Single-Dose, Phase 1/2 Clinical Trial of ABO-102 Gene Therapy for Sanfilippo Syndrome Type A (Mucopolysaccharidosis IIIA)
Kevin Flanigan, M.D., Nationwide Children’s Hospital
Related Articles